Acute and Repeated Treatment with 5-PAHSA or 9-PAHSA Isomers Does Not Improve Glucose Control in Mice
- Cell Metab. 2018 Aug 7;28(2):217-227.e13. doi: 10.1016/j.cmet.2018.05.028.
- 1. Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, Bldg. H821, 65926 Frankfurt am Main, Germany.
- 2. Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, Bldg. H821, 65926 Frankfurt am Main, Germany. Electronic address: [email protected].
- 3. Institut für Organische Chemie, Johannes Gutenberg Universität Mainz, Duesbergweg 10-14, 55128 Mainz, Germany.
- 4. Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, Bldg. H821, 65926 Frankfurt am Main, Germany. Electronic address: [email protected].
Fatty acid esters of hydroxylated fatty acids (FAHFAs) were discovered as a novel class of endogenous mammalian lipids whose profound effects on metabolism have been shown. In the current study, in vitro and in vivo the metabolic effects of two of these FAHFAs, namely palmitic acid-5- (or -9) -hydroxy-stearic acid (5- or 9-PAHSA, respectively) were profiled. In DIO mice fed with differentially composed low- or high-fat diets, acute and subchronic treatment with 5-PAHSA and 9-PAHSA alone, or in combination, did not significantly improve the deranged metabolic status. Neither racemic 5- or 9-PAHSA, nor the enantiomers were able to: (1) increase basal or insulin-stimulated glucose uptake in vitro, (2) stimulate GLP-1 release from GLUTag cells, or (3) induce GSIS in rat, mouse, or human islets or in a human pancreatic β cell line. Therefore, our data do not support the further development of PAHSAs or their derivatives for the control of Insulin resistance and hyperglycemia.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
-
Research Areas: Others
-
Research Areas: Inflammation/Immunology
-
-
Research Areas: Others
-
Research Areas: Others